| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,003 | 0,009 | 07:00 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| WESANA HEALTH Aktie jetzt für 0€ handeln | |||||
| 24.01. | Wesana Health Holdings Inc.: Wesana Health Announces Change to The Board of Directors | 834 | Newsfile | Chicago, Illinois and Toronto, Ontario--(Newsfile Corp. - January 24, 2025) - Wesana Health Holdings Inc. (CSE: WESA.X) (OTC Pink: WSNAF) (the "Company") is pleased to announce the appointment of Mark... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 40,280 | -0,05 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| ESSILORLUXOTTICA | 276,00 | +1,06 % | JPMORGAN stuft EssilorLuxottica auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für EssilorLuxottica mit einem Kursziel von 345 Euro auf "Overweight" belassen. Nach ihrem jüngsten Ausblick auf 2026 kommentierte... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,084 | +5,66 % | Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 138,55 | +1,32 % | Align Technology: Wenn der Markt zu lange skeptisch bleibt | ||
| NUGEN MEDICAL DEVICES | 0,018 | -12,87 % | NuGen Medical: Kurs explodiert nach wichtiger News! | ||
| HEALWELL AI | 0,525 | -2,42 % | Court order prompts Well Health, Healwell to hand over records in merger probe | ||
| INMODE | 12,375 | +1,43 % | InMode Ltd.: InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins | YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,610 | +0,33 % | Atossa Therapeutics Inc: Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy | Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval
SEATTLE... ► Artikel lesen | |
| SPINEWAY | 0,152 | +17,65 % | Spineway: Revenue growth in the third quarter | Ecully, October 14, 2025 - 6:30 p.m. SPINEWAYRevenue growth in the third quarter In thousands of euros20252024Change as a %Q3 revenue3,0452,575 +18%Q2 revenue2,7453,465-21% Q1 revenue2,8283,070-8%9M... ► Artikel lesen | |
| ELEVANCE HEALTH | 293,70 | -0,34 % | ELV-Trilog führt zu selektiver Kreislaufwirtschaft | ||
| MOUNTAIN VALLEY MD | 0,009 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
| VERU | 2,270 | +2,25 % | Veru Inc.: Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress | -- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an... ► Artikel lesen | |
| ONTRAK | 0,184 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.08.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 26.08.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.08.2025.ISIN NameAU0000006934 NEW... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 | All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T programAcquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR- Antagonist, Phase 3-ready) and TPST-1495... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 2,246 | +1,58 % | Here's Why You Should Retain CLOV Stock in Your Portfolio Now |